A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. (2014)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/ana.24188

PubMed Identifier: 24853080

Publication URI: http://europepmc.org/abstract/MED/24853080

Type: Journal Article/Review

Volume: 76

Parent Publication: Annals of neurology

Issue: 2

ISSN: 0364-5134